To read the full story, subscribe or sign in.

CSPC NBP gains China rights to Harbour’s batoclimab for ¥150M up front

Oct. 11, 2022

CSPC NBP Pharmaceuticals Co. Ltd. entered an agreement that will grant it exclusive rights to Harbour Biomed Co. Ltd.’s anti-FcRn antibody, batoclimab (HBM-9161), in greater China, including Hong Kong, Macau and Taiwan.

BioWorld BioWorld Asia Deals and M&A Immune Asia-Pacific China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Jan. 27, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2022.

Biogen, Eisai win FDA clearance for AD therapy Leqembi

BioWorld

As expected, the U.S. FDA gave its go-ahead to lecanemab, an amyloid-beta binder for mild cognitive impairment caused by Alzheimer’s disease (AD) and mild AD –...

J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

BioWorld

After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...

Upgrade your daily dose of biopharma and medtech news

CSPC NBP gains China rights to Harbour’s batoclimab for ¥150M up front